Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.86 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.48 |
| ▸ | EGFR | P00533 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19986670 | 1.00 | BTK (0.86) | BTKERBB2EGFR | |
| SCHEMBL16440887 | 0.97 | BTK (0.80) | BTKERBB2EGFR | |
| SCHEMBL166896 | 0.93 | BTK (1.00) | BTKERBB2EGFR | |
| SCHEMBL19993798 | 0.93 | BTK (1.00) | BTKERBB2EGFR | |
| SCHEMBL19728633 | 0.84 | BTK (0.62) | BTKERBB2EGFR | |
| SCHEMBL122280 | 0.84 | BTK (1.00) | BTKEGFR | |
| SCHEMBL18905245 | 0.84 | BTK (0.61) | BTKERBB2EGFR | |
| SCHEMBL169757 | 0.84 | BTK (0.85) | BTKERBB2EGFR | |
| SCHEMBL124181 | 0.83 | BTK (0.82) | BTKERBB2EGFR | |
| SCHEMBL174843 | 0.82 | BTK (0.80) | BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016434-B2 | Methods for the treatment of HER2 amplified cancer | PHARMACYCLICS LLC (US) | 2018-07-10 | — | — | US | disclosed |
| US-9844552-B2 | Methods of treating fibrosis | PHARMACYCLICS LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9724349-B2 | Methods for the treatment of HER2 amplified cancer | PHARMACYCLICS LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170027941-A1 | Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof | PHARMACYCLICS LLC | 2017-02-02 | — | — | US | disclosed |
| US-9545407-B2 | Formulations of a bruton's tyrosine kinase inhibitor | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160287592-A1 | IBRUTINIB COMBINATION THERAPY | PHARMACYCLICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160199376-A1 | METHODS OF TREATING FIBROSIS | PHARMACYCLICS LLC | 2016-07-14 | — | — | US | disclosed |
| US-20160038496-A1 | NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC | 2016-02-11 | — | — | US | disclosed |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | PHARMACYCLICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160008366-A1 | BTK INHIBITORS FOR THE TREATMENT OF CNS MALIGNANCIES | PHARMACYCLICS LLC | 2016-01-14 | — | — | US | disclosed |
| US-20150157634-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008366-A1 | BTK INHIBITORS FOR THE TREATMENT OF CNS MALIGNANCIES | BTK, SYK, ABL1 | BTK 1/4885ERBB2 56/4885EGFR 202/4885 |
| US-20150157634-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | FCGR3B, BTK, IGLV6-57 | BTK 2/4885ERBB2 1670/4885EGFR 1605/4885 |
| US-20160038496-A1 | NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, LYN, SYK | BTK 1/4885ERBB2 53/4885EGFR 870/4885 |
| US-20170027941-A1 | Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof | BTK, ERBB2, ERBB3 | BTK 1/4885ERBB2 2/4885EGFR 12/4885 |
| US-20160199376-A1 | METHODS OF TREATING FIBROSIS | MYLK, MMP1, MMP8 | BTK 18/4885ERBB2 1427/4885EGFR 1613/4885 |
| US-10016434-B2 | Methods for the treatment of HER2 amplified cancer | ERBB2, EGFR, ERBB3 | BTK 10/4885ERBB2 1/4885EGFR 2/4885 |
| US-20160287592-A1 | IBRUTINIB COMBINATION THERAPY | BTK, SYK, LYN | BTK 1/4885ERBB2 51/4885EGFR 679/4885 |
| US-20160022683-A1 | COMBINATIONS OF BRUTON'S TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS | BTK, CYP2E1, CYP3A43 | BTK 1/4885ERBB2 113/4885EGFR 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.